欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2015, Vol. 20 ›› Issue (5): 546-551.

• 临床药理学 • 上一篇    下一篇

ERCC1蛋白的表达与晚期食管癌含顺铂方案化疗疗效的临床观察

张虹1,2, 顾康生1   

  1. 1安徽医科大学第一附属医院肿瘤科,合肥 230022,安徽;
    2歙县人民医院肿瘤科,黄山 245200,安徽
  • 收稿日期:2014-12-01 修回日期:2015-02-27 发布日期:2015-06-11
  • 通讯作者: 顾康生,男,博士,教授,主任医师,研究方向:肿瘤的个体化治疗。Tel: 0551-62923504 E-mail: gks63@tom.com
  • 作者简介:张虹,在读硕士,住院医师,研究方向:食管癌的个体化治疗。Tel: 0559-6530292 E-mail: zhanghong_198507@163.com

Clinical observation of ERCC1 protein expression and cisplatin based chemotherapy on advanced esophageal cancer

ZHANG Hong1,2, GU Kang-sheng1   

  1. 1 Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, China;
    2 Department of Oncology, People's Hospital of She County, Huangshan 245200, Auhui, China
  • Received:2014-12-01 Revised:2015-02-27 Published:2015-06-11

摘要: 目的: 探讨晚期食管癌患者癌组织中切除修复交叉互补基因1(ERCC1)蛋白的表达与含顺铂方案联合化疗疗效的相关性。方法: 回顾性检测98例晚期食管癌患者肿瘤组织中ERCC1蛋白的表达,观察患者接受含顺铂方案的联合化疗的疗效,分析ERCC1表达与客观有效率、疾病控制率、无进展生存期、总生存期之间的关系。结果: 98例患者ERCC1表达阳性率为 56.1%(55/98),总疾病控制率为 70.4%(69/98),ERCC1表达阴性组的客观有效率(76.7%)优于表达阳性组(38.2%), 差异有统计学意义(χ2=14.506, P=0.000);ERCC1表达阴性组的疾病控制率(88.4%)优于表达阳性组(56.4%), 差异有统计学意义(χ2=11.867, P=0.001);ERCC1表达阳性和阴性的两组无进展生存期和总生存期变化相近(P>0.05)。结论: 晚期食管癌病理组织中ERCC1阴性表达患者疗效近期有效率优于ERCC1阳性表达患者。

关键词: 食管肿瘤, 顺铂, 切除修复交叉互补基因1

Abstract: AIM: To investigate the relationship between ERCC1 expression in advanced esophageal cancer and the chemotherapy effect treated with cisplatin.METHODS: 98 pathological specimens of advanced esophageal cancer patients were collected to detect ERCC1 expression. All patients received cisplatin chemotherapy The researchers observe the effect of patients receiving cisplatin-containing combination chemotherapy programs, and analyze the relationships between ERCC1 expression and objective response rate, disease control rate, progression-free survival, overall survival.RESULTS: In all 98 patients, the positive rate of ERCC1 expression was 56.1%(55/98), the overall disease control rate was 70.4% (69/98), while objective response rate in negative group of ERCC 1 expression (76.7%) was higher than that in positive group (38.2%), which showed statistical difference (χ2=14.506, P=0.000); disease control rate in negative group of ERCC1 expression (88.4%) was higher than that in positive group (56.4%), which showed statistical difference (χ2=11.867, P=0.001). The expression of ERCC1 two groups progression-free survival and overall survival difference between positive and negative have similar changes (P>0.05).CONCLUSION: The recent efficient of patients with ERCC1 negative expression in esophageal cancer pathological tissue is better than that of positive ERCC1 expression.

Key words: esophageal neoplasms, cisplatin, ERCC1

中图分类号: